149 related articles for article (PubMed ID: 34534734)
1. Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects.
Li T; Li C; Yang J; Guo M; Cao Z; Wang X; Jiang N; Zhai X
Bioorg Med Chem; 2021 Oct; 47():116396. PubMed ID: 34534734
[TBL] [Abstract][Full Text] [Related]
2. Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations.
Cao M; Chen Y; Zhao T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115715. PubMed ID: 33069079
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
4. Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects.
Li Z; Guo M; Cao M; Zhao T; Li M; Zhai X
Bioorg Med Chem; 2021 May; 37():116108. PubMed ID: 33756437
[TBL] [Abstract][Full Text] [Related]
5. Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.
Zhu M; Li W; Zhao T; Chen Y; Li T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115719. PubMed ID: 33069075
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation N
Xing L; Jing T; Zhang J; Guo M; Miao X; Jiang F; Zhai X
Bioorg Chem; 2018 Dec; 81():689-699. PubMed ID: 30268049
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects.
Cao Z; Zhang J; Guo M; Shao B; Wei X; Li S; Wang P; Zhai X
Bioorg Chem; 2023 Jul; 136():106563. PubMed ID: 37121107
[TBL] [Abstract][Full Text] [Related]
8. Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.
Guo M; Zuo D; Zhao T; Li X; Cao J; Qiu Y; Wei S; Zhai X
Eur J Med Chem; 2021 Mar; 214():113259. PubMed ID: 33581554
[TBL] [Abstract][Full Text] [Related]
9. An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects.
Lei H; Jia F; Cao M; Wang J; Guo M; Zhu M; Zuo D; Zhai X
Bioorg Med Chem; 2019 Oct; 27(20):115051. PubMed ID: 31492532
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel ALK inhibitors.
Wang X; Hu Y; Zou X; Wang P; Yue H; Guo M; Li Z; Gong P
Bioorg Med Chem; 2022 Jul; 66():116794. PubMed ID: 35576654
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents.
Wu F; Yao H; Li W; Zhang N; Fan Y; Chan ASC; Li X; An B
Bioorg Med Chem Lett; 2021 Sep; 48():128253. PubMed ID: 34245852
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
Pan T; Dan Y; Guo D; Jiang J; Ran D; Zhang L; Tian B; Yuan J; Yu Y; Gan Z
Eur J Med Chem; 2021 Nov; 224():113672. PubMed ID: 34237620
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a PROTAC targeting ALK with in vivo activity.
Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1.
Wang Y; Zhang G; Hu G; Bu Y; Lei H; Zuo D; Han M; Zhai X; Gong P
Eur J Med Chem; 2016 Nov; 123():80-89. PubMed ID: 27474925
[TBL] [Abstract][Full Text] [Related]
16. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
[TBL] [Abstract][Full Text] [Related]
17. Identification of highly potent 2,4-diarylaminopyrimidine analogs of a typical piperidinyl-4-ol moiety as promising antitumor ALK inhibitors.
Liu S; Wang F; Yang J; Su G; Cao Z; Shan M; Zhai X
Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300416. PubMed ID: 37737557
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors.
Chen H; Li R; Ning X; Zhao X; Jin Y; Yin Y
Eur J Med Chem; 2019 Sep; 178():141-153. PubMed ID: 31177074
[TBL] [Abstract][Full Text] [Related]
19. Fragment-based discovery of novel phenyltriazolyl derivatives as allosteric type-I
Cui Y; Tan Z; Liu S; Cao Z; Shao B; Guo M; Jiang N; Zhai X
Bioorg Med Chem Lett; 2022 Nov; 75():128990. PubMed ID: 36113668
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I
Miao X; Xing L; Guo M; Zhang H; Liu S; Yin S; Gong P; Zhang D; Zhai X
Bioorg Chem; 2020 Jan; 94():103456. PubMed ID: 31787343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
